Bath & Body Works

Bath & Body Works reported Q2 adjusted EPS of $0.62, far above the $0.24 estimate, on revenue of $1.5B (in line). Net income surged 84% YoY. But total sales fell 2.3% YoY, and the company issued a weak Q3 outlook with EPS of just $0.07-$0.12 and net sales down 2.5%-5%. FY26 net sales are expected to decline 2.5%-4%. Management said underlying trends remain pressured.

Analyst rating changes across multiple sectors. Upgrades: AMX (JPMorgan), AKR (KeyBanc), BBWI (Citi), STRW (Compass Point), DUOL (DA Davidson), COLD (BofA). Downgrades: EYPT (RBC, H.C. Wainwright), ATHM (BofA), TIGO (JPMorgan), ANF (Raymond James), NCLH (Mizuho), KRG (KeyBanc), METC (Baird), AMRC (Baird), GSAT (Craig-Hallum).